82 related articles for article (PubMed ID: 9576283)
1. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma.
Mita Y; Aoyagi Y; Yanagi M; Suda T; Suzuki Y; Asakura H
Cancer; 1998 May; 82(9):1643-8. PubMed ID: 9576283
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma.
Wang CS; Lin CL; Lee HC; Chen KY; Chiang MF; Chen HS; Lin TJ; Liao LY
World J Gastroenterol; 2005 Oct; 11(39):6115-9. PubMed ID: 16273636
[TBL] [Abstract][Full Text] [Related]
3. Association of Serum Levels and Immunohistochemical Labelling of Des-Gamma-Carboxy-Prothrombin in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.
Chabert S; Iesari S; Dahlqvist G; Komuta M; Baldin P; Favi E; Coubeau L
Diagnostics (Basel); 2024 Apr; 14(9):. PubMed ID: 38732309
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic Signature of 3D Hierarchical Porous Chip Enriched Exosomes for Early Detection and Progression Monitoring of Hepatocellular Carcinoma.
Yi K; Wang Y; Rong Y; Bao Y; Liang Y; Chen Y; Liu F; Zhang S; He Y; Liu W; Zhu C; Wu L; Peng J; Chen H; Huang W; Yuan Y; Xie M; Wang F
Adv Sci (Weinh); 2024 Apr; 11(14):e2305204. PubMed ID: 38327127
[TBL] [Abstract][Full Text] [Related]
5. Advanced Nanoencapsulation-Enabled Ultrasensitive Analysis: Unraveling Tumor Extracellular Vesicle Subpopulations for Differential Diagnosis of Hepatocellular Carcinoma via DNA Cascade Reactions.
Li X; Liu Y; Fan Y; Tian G; Shen B; Zhang S; Fu X; He W; Tao X; Ding X; Li X; Ding S
ACS Nano; 2024 Apr; 18(17):11389-11403. PubMed ID: 38628141
[TBL] [Abstract][Full Text] [Related]
6. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
Huang C; Xiao X; Zhou L; Chen F; Wang J; Hu X; Gao C;
J Clin Lab Anal; 2023 Dec; 37(23-24):e24990. PubMed ID: 38063322
[TBL] [Abstract][Full Text] [Related]
7. Zinc Oxide Nanoparticles as Diagnostic Tool for Cancer Cells.
Ibraheem S; Kadhim AA; Kadhim KA; Kadhim IA; Jabir M
Int J Biomater; 2022; 2022():2807644. PubMed ID: 36387955
[TBL] [Abstract][Full Text] [Related]
8. Effects of Metal Oxide Nanoparticles in Zebrafish.
d'Amora M; Schmidt TJN; Konstantinidou S; Raffa V; De Angelis F; Tantussi F
Oxid Med Cell Longev; 2022; 2022():3313016. PubMed ID: 35154565
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment.
Anjum S; Hashim M; Malik SA; Khan M; Lorenzo JM; Abbasi BH; Hano C
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572797
[TBL] [Abstract][Full Text] [Related]
10. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Colli A; Nadarevic T; Miletic D; Giljaca V; Fraquelli M; Štimac D; Casazza G
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013346. PubMed ID: 33855699
[TBL] [Abstract][Full Text] [Related]
11. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis.
Wang X; Zhang Y; Yang N; He H; Tao X; Kou C; Jiang J
Biomed Res Int; 2020; 2020():5087643. PubMed ID: 33015170
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma.
Wu M; Liu Z; Li X; Zhang A; Li N
Onco Targets Ther; 2020; 13():827-840. PubMed ID: 32095079
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma.
Qi F; Zhou A; Yan L; Yuan X; Wang D; Chang R; Zhang Y; Shi F; Han X; Hou J; Wei L; Zhang X
J Clin Lab Anal; 2020 May; 34(5):e23158. PubMed ID: 31821607
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markers.
Seino S; Tsuchiya A; Watanabe Y; Kawata Y; Kojima Y; Ikarashi S; Yanai H; Nakamura K; Kumaki D; Hirano M; Funakoshi K; Aono T; Sakai T; Sakata J; Takamura M; Kawai H; Yamagiwa S; Wakai T; Terai S
Oncotarget; 2018 Apr; 9(31):21844-21860. PubMed ID: 29774107
[TBL] [Abstract][Full Text] [Related]
16. Should AFP (or any biomarkers) be used for HCC surveillance?
Ahmed Mohammed HF; Roberts LR
Curr Hepatol Rep; 2017 Jun; 16(2):137-145. PubMed ID: 29085770
[TBL] [Abstract][Full Text] [Related]
17. Differences in the impact of prognostic factors for hepatocellular carcinoma over time.
Toyoda H; Kumada T; Tada T; Yama T; Mizuno K; Sone Y; Maeda A; Kaneoka Y; Akita T; Tanaka J
Cancer Sci; 2017 Dec; 108(12):2438-2444. PubMed ID: 28945309
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.
Yu R; Tan Z; Xiang X; Dan Y; Deng G
BMC Cancer; 2017 Sep; 17(1):608. PubMed ID: 28863782
[TBL] [Abstract][Full Text] [Related]
19. Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma.
Kiyokawa H; Yasuda H; Oikawa R; Okuse C; Matsumoto N; Ikeda H; Watanabe T; Yamamoto H; Itoh F; Otsubo T; Yoshimura T; Yoshida E; Nakagawa M; Koshikawa N; Seiki M
Cancer Sci; 2017 Jul; 108(7):1432-1439. PubMed ID: 28418226
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
